Publications by authors named "E Haura"
Introduction: Recent advances in the treatment of -mutant non-small cell lung cancer (NSCLC) have led to the development of KRAS inhibitors, such as sotorasib and adagrasib. However, resistance and disease progression remain significant challenges. In this study, we investigated the therapeutic potential of combining trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody-drug conjugate, with sotorasib in -mutant NSCLC, while also evaluating HER2 expression in NSCLC samples.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates gene expression differences in Small Cell Lung Cancer (SCLC) to find potential biomarkers that could enhance clinical testing and treatment options.
- Researchers used RNA expression profiling on tumor samples from SCLC patients and found a strong correlation between their methods and traditional sequencing techniques, revealing varying gene expressions between primary and metastatic sites.
- The findings suggest that profiling SCLC at a clinical level can aid in identifying specific subtypes, which could be crucial for designing more effective clinical trials and targeted therapies for patients.
Article Synopsis
- Cancer-associated fibroblasts (CAFs) promote tumor growth and alter cancer cells' response to drugs, especially in non-small cell lung cancer (NSCLC) treated with ALK tyrosine kinase inhibitors (TKIs).
- Research identified HGF-MET signaling and the fibronectin-integrin pathway as key mechanisms in CAF-mediated drug resistance, with integrin β1 activation in cancer cells found through flow cytometry.
- Combining MET and integrin inhibitors with ALK TKIs showed greater anti-tumor effects in mouse models, highlighting the need for targeting multiple signaling pathways to improve cancer treatment outcomes.
Immunotherapy response is associated with the presence of conventional dendritic cells (cDCs). cDC type 1 (cDC1) is critically important for CD8+ T cell activation, cDC type 2 (cDC2) regulates CD4+ T cell responses, and mature regulatory cDCs may dampen T cell responses in the tumor microenvironment (TME). However, we lack a clear understanding of cDC distribution in the human TME, cDC prevalence in metastatic sites, and cDC differences in early- versus late-stage disease.
View Article and Find Full Text PDFArchived tumor specimens are routinely preserved by formalin fixation and paraffin embedding. Despite the conventional wisdom that proteomics might be ineffective due to the cross-linking and pre-analytical variables, these samples have utility for both discovery and targeted proteomics. Building on this capability, proteomics approaches can be used to maximize our understanding of cancer biology and clinical relevance by studying preserved tumor tissues annotated with the patients' medical histories.
View Article and Find Full Text PDF